Jaguar Health Files 8-K: Agreements, Equity Sales, Bylaw Changes
Ticker: JAGX · Form: 8-K · Filed: 2025-09-11T00:00:00.000Z
Sentiment: neutral
Topics: definitive-agreement, equity-sale, corporate-action
Related Tickers: JAGX
TL;DR
Jaguar Health (JAGX) filed an 8-K on 9/9/25 covering new deals, stock sales, and bylaw updates. Watch closely.
AI Summary
On September 9, 2025, Jaguar Health, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, unregistered sales of equity securities, and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, indicating ongoing corporate activities and potential financial transactions.
Why It Matters
This filing signals significant corporate actions by Jaguar Health, Inc., including potential new agreements and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity securities and material definitive agreements, which can introduce financial and operational risks.
Key Numbers
- 001-36714 — Commission File Number (Identifies the company's SEC filing history)
- 46-2956775 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- September 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 200 Pine Street Suite 400 San Francisco, California 94104 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Jaguar Health, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text excerpt.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided text.
What specific amendments were made to Jaguar Health's articles of incorporation or bylaws?
The filing states that there were amendments to articles of incorporation or bylaws, but the exact nature of these amendments is not specified in the excerpt.
When was Jaguar Health, Inc. formerly known as Jaguar Animal Health, Inc. and when did the name change occur?
The company was formerly known as Jaguar Animal Health, Inc., and the date of the name change was August 30, 2013.
What is the SIC code for Jaguar Health, Inc.?
The Standard Industrial Classification (SIC) code for Jaguar Health, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,307 words · 17 min read · ~14 pages · Grade level 20 · Accepted 2025-09-11 16:30:18
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Stock Mar
- $2.38 million — gregate purchase price of approximately $2.38 million (the "Private Placement"). The Private
- $2,500 — e quotient obtained by dividing (i) the $2,500 stated value of each share of Series N
- $1 — he Certificate of Designation, equal to $1.20, subject to adjustments), which amou
Filing Documents
- d947025d8k.htm (8-K) — 57KB
- d947025dex31.htm (EX-3.1) — 57KB
- d947025dex101.htm (EX-10.1) — 132KB
- 0001193125-25-201351.txt ( ) — 417KB
- jagx-20250909.xsd (EX-101.SCH) — 3KB
- jagx-20250909_lab.xml (EX-101.LAB) — 18KB
- jagx-20250909_pre.xml (EX-101.PRE) — 11KB
- d947025d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Designation of Preferences, Rights and Limitations of Series N Perpetual Preferred Stock. 10.1 Form of Securities Purchase Agreements. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. Date: September 11, 2025 By: /s/ Lisa A. Conte Lisa A. Conte Chief Executive Officer & President